Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis
Structured PICO
Do small interfering RNA (siRNA) therapies reduce triglycerides and improve lipid profiles in patients with hypertriglyceridemia and mixed dyslipidemia?
P
Population
Patients with hypertriglyceridemia (HTG) and mixed dyslipidemia
I
Intervention
Small interfering RNA (siRNA) therapies (including APOC3-targeted and ANGPTL3-targeted treatments)
O
Outcome
Reduction in triglycerides, improvement in lipid profiles (including HDL-C and LDL-C), and safetysurrogate
siRNA therapies targeting APOC3 and ANGPTL3 are effective and safe for reducing triglycerides and modulating broader lipid profiles in patients with hypertriglyceridemia and mixed dyslipidemia.
Abstract
siRNA therapies demonstrate significant efficacy in reducing triglycerides and improving lipid profiles in patients with HTG and mixed dyslipidemia. APOC3-targeted treatments primarily reduce triglycerides while increasing HDL-C, whereas ANGPTL3-targeted therapies offer broader lipid modulation, including substantial reductions in LDL-C. Both therapies demonstrate favorable safety profiles.
Like
Bookmark
Share
View Full Paper
Like
Bookmark
Share
View Full Paper
Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis | Synapse